Image source: Adobe Stock/rh2010

News • Methylation pattern analysis

cfSort: New tool could improve liquid biopsy

A research team led by Xianghong Jasmine Zhou, PhD, professor of Pathology and Laboratory Medicine at David Geffen School of Medicine at the University of California, Los Angeles (UCLA), has made an important advancement to address one of the major challenges in cell-free DNA (cfDNA) testing, also known as liquid biopsy.

They’ve identified specific methylation patterns unique to each tissue, potentially helping to Identify the specific tissue or organ associated with cfDNA alterations picked up by testing, a critical challenge for accurate diagnosis and monitoring of diseases. 

Cell-free DNA has significant potential in disease detection and monitoring. However, accurately quantifying tissue-derived cfDNA has proven challenging with current methods, among them determining the tissue origin of cfDNA fragments detected in these tests. 

In a new study, published in Proceedings of the National Academy of Sciences (PNAS), a peer reviewed journal of the National Academy of Sciences (NAS), the team developed a comprehensive and high-resolution methylation atlas based on a vast dataset of 521 noncancerous tissue samples representing 29 major types of human tissues. They call the approach cfSort, and showed it successfully identified specific methylation patterns unique to each tissue at the fragment level and validated these findings using additional datasets.

We have shown that the cfSort outperformed the existing methods in terms of accuracy and detection limit: making more accurate tissue fraction estimation and distinguishing a lower level of tissue-derived cfDNA

Shuo Li

Going further, the team illustrated the clinical applications of cfSort through two potential uses: aiding in disease diagnosis and monitoring treatment side effects. By estimating the tissue-derived cfDNA fraction using cfSort, they were able to assess and predict clinical outcomes in patients. “We have shown that the cfSort outperformed the existing methods in terms of accuracy and detection limit: making more accurate tissue fraction estimation and distinguishing a lower level of tissue-derived cfDNA,” said first author Shuo Li. “In addition, the cfSort demonstrated nearly perfect robustness toward the unseen local fluctuations of tissue compositions, indicating its wide applicability to diverse individuals.” 

Xianghong Jasmine Zhou and two co-authors. are co-founders of EarlyDiagnostics Inc. See article for full list of disclosures. 


Source: UCLA Health

05.07.2023

Read all latest stories

Related articles

Photo

Article • Cancer diagnostics I

Ambiguity calls for a second opinion

Each year, approximately 1.6 million women in the USA have breast biopsies to diagnose or rule out cancer. Pathological diagnosis is considered the gold standard – how accurate are these…

Photo

News • Biomarker-based predictions

AI drives precision oncology for colorectal cancer

For the first time, researchers show that AI-based predictions can deliver comparable results to clinical tests on biopsies of patients with colorectal cancer (CRC).

Photo

News • Microfluidics and electrochemical transduction

Paper-based device for rapid diagnosis of lung diseases

A new device that combines microfluidics on paper, electrochemical transduction and immunoassays on magnetic nanoparticles is useful for easy and rapid diagnosis of lung diseases.

Related products

CliniSys – Anatomical Pathology Laboratory

Information Technology

CliniSys – Anatomical Pathology Laboratory

Clinisys Deutschland GmbH
Fujifilm Wako – Autokit Total Ketone Bodies Assay

Clinical Chemistry

Fujifilm Wako – Autokit Total Ketone Bodies Assay

FUJIFILM Wako Chemicals Europe GmbH
KABE Labortechnik – Consumables for pathology / histology

Histology Equipment

KABE Labortechnik – Consumables for pathology / histology

KABE LABORTECHNIK GmbH
Mesalvo – LabCentre

LIS, Middleware, POCT

Mesalvo – LabCentre

Mesalvo Mannheim GmbH
Sarstedt – Tempus600 Vita

Sample Logistics

Sarstedt – Tempus600 Vita

SARSTEDT AG & CO. KG
Shimadzu – LCMS-8060NX CL (IVD) / LCMS-8060 NX (RUO)

Mass Spectrometry

Shimadzu – LCMS-8060NX CL (IVD) / LCMS-8060 NX (RUO)

Shimadzu Europa GmbH
Subscribe to Newsletter